Please login to the form below

Not currently logged in
Email:
Password:

Arresto Biosciences

This page shows the latest Arresto Biosciences news and features for those working in and with pharma, biotech and healthcare.

Gilead chalks up trial success for new NASH drug

Gilead chalks up trial success for new NASH drug

The phase II trial is looking at selonsertib (GS-4997) on its own or in combination with Gilead's other NASH candidate simtuzumab - acquired along with Arresto Biosciences for $225m in

Latest news

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    The antibody - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - has previously failed to show efficacy in a pancreatic cancer trial.

  • Gilead's simtuzumab fails pancreatic cancer trial Gilead's simtuzumab fails pancreatic cancer trial

    Simtuzumab - which was acquired by Gilead when it bought Arresto Biosciences for $225m in 2010 - is also in phase II trials for idiopathic pulmonary fibrosis, myelofibrosis, non-alcoholic steatohepatitis (NASH) and

  • Gilead to acquire Calistoga

    The Calistoga acquisition comes on the heels of the company's acquisitions last year of two other small biotech companies, CGI Pharmaceuticals and Arresto Biosciences, both of which are also developing ... Gilead acquired Arresto for $225m plus potential

  • Gilead to acquire Arresto Bioscences

    Gilead to acquire Arresto Bioscences. Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels. ... Gilead will acquire Arresto Biosciences for $225m plus potential future payments based on sales levels.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
wethepeople

wethepeople are bringing human appeal back to brand communications. Our approach allows us to create strategies, ideas and experiences that...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics